402 related articles for article (PubMed ID: 26493563)
1. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.
Shanavas M; Popat U; Michaelis LC; Fauble V; McLornan D; Klisovic R; Mascarenhas J; Tamari R; Arcasoy MO; Davies J; Gergis U; Ukaegbu OC; Kamble RT; Storring JM; Majhail NS; Romee R; Verstovsek S; Pagliuca A; Vasu S; Ernst B; Atenafu EG; Hanif A; Champlin R; Hari P; Gupta V
Biol Blood Marrow Transplant; 2016 Mar; 22(3):432-40. PubMed ID: 26493563
[TBL] [Abstract][Full Text] [Related]
2. Effect of pre-transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis.
Cyriac S; Prem S; Salas MQ; Chen S; Al-Shaibani Z; Lam W; Law A; Gupta V; Michelis FV; Kim DDH; Lipton J; Kumar R; Mattsson J; Viswabandya A
Eur J Haematol; 2021 Nov; 107(5):517-528. PubMed ID: 34260760
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.
Gupta V; Hari P; Hoffman R
Blood; 2012 Aug; 120(7):1367-79. PubMed ID: 22700718
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.
Jaekel N; Behre G; Behning A; Wickenhauser C; Lange T; Niederwieser D; Al-Ali HK
Bone Marrow Transplant; 2014 Feb; 49(2):179-84. PubMed ID: 24292520
[TBL] [Abstract][Full Text] [Related]
5. Myelofibrosis: to transplant or not to transplant?
Devlin R; Gupta V
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):543-551. PubMed ID: 27913527
[TBL] [Abstract][Full Text] [Related]
6. Myelofibrosis-When Do We Select Transplantation or Non-transplantation Therapeutic Options?
Viswabandya A; Devlin R; Gupta V
Curr Hematol Malig Rep; 2016 Feb; 11(1):6-11. PubMed ID: 26659587
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789
[TBL] [Abstract][Full Text] [Related]
8. Practical management of myelofibrosis with ruxolitinib.
Ho PJ; Marlton P; Tam C; Stevenson W; Ritchie D; Bird R; Dunlop LC; Durrant S; Ross DM
Intern Med J; 2015 Dec; 45(12):1221-30. PubMed ID: 26648193
[TBL] [Abstract][Full Text] [Related]
9. Splenectomy following JAK1/JAK2 inhibitor therapy in patients with myelofibrosis undergoing allogeneic stem cell transplantation.
Barabanshikova MV; Zubarovsky IN; Savrasov VM; Korolkov AJ; Baykov VV; Botina AV; Vlasova JJ; Moiseev IS; Darskaya EI; Morozova EV; Afanasyev BV
Hematol Oncol Stem Cell Ther; 2019 Sep; 12(3):140-145. PubMed ID: 30978308
[TBL] [Abstract][Full Text] [Related]
10. Controversies and dilemmas in allogeneic transplantation for myelofibrosis.
Shanavas M; Gupta V
Best Pract Res Clin Haematol; 2014 Jun; 27(2):165-74. PubMed ID: 25189727
[TBL] [Abstract][Full Text] [Related]
11. How we manage JAK inhibition in allogeneic transplantation for myelofibrosis.
Ballinger TJ; Savani BN; Gupta V; Kroger N; Mohty M
Eur J Haematol; 2015 Feb; 94(2):115-9. PubMed ID: 25256963
[TBL] [Abstract][Full Text] [Related]
12. A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.
Ho PJ; Bajel A; Burbury K; Dunlop L; Durrant S; Forsyth C; Perkins AC; Ross DM
Intern Med J; 2017 Mar; 47(3):262-268. PubMed ID: 28260257
[TBL] [Abstract][Full Text] [Related]
13. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.
Cervantes F; Vannucchi AM; Kiladjian JJ; Al-Ali HK; Sirulnik A; Stalbovskaya V; McQuitty M; Hunter DS; Levy RS; Passamonti F; Barbui T; Barosi G; Harrison CN; Knoops L; Gisslinger H;
Blood; 2013 Dec; 122(25):4047-53. PubMed ID: 24174625
[TBL] [Abstract][Full Text] [Related]
14. Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?
Lestang E; Peterlin P; Le Bris Y; Dubruille V; Delaunay J; Godon C; Theisen O; Blin N; Mahe B; Gastinne T; Garnier A; Touzeau C; Voldoire M; Bene MC; Le Gouill S; Milpied N; Mohty M; Moreau P; Guillaume T; Chevallier P
Eur J Haematol; 2017 Jul; 99(1):60-69. PubMed ID: 28370306
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic hematopoietic cell transplantation for chronic myelofibrosis in Australia and New Zealand: older recipients receiving myeloablative conditioning at increased mortality risk.
Nivison-Smith I; Dodds AJ; Butler J; Bradstock KF; Ma DD; Simpson JM; Szer J
Biol Blood Marrow Transplant; 2012 Feb; 18(2):302-8. PubMed ID: 21620988
[TBL] [Abstract][Full Text] [Related]
16. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.
Porpaczy E; Tripolt S; Hoelbl-Kovacic A; Gisslinger B; Bago-Horvath Z; Casanova-Hevia E; Clappier E; Decker T; Fajmann S; Fux DA; Greiner G; Gueltekin S; Heller G; Herkner H; Hoermann G; Kiladjian JJ; Kolbe T; Kornauth C; Krauth MT; Kralovics R; Muellauer L; Mueller M; Prchal-Murphy M; Putz EM; Raffoux E; Schiefer AI; Schmetterer K; Schneckenleithner C; Simonitsch-Klupp I; Skrabs C; Sperr WR; Staber PB; Strobl B; Valent P; Jaeger U; Gisslinger H; Sexl V
Blood; 2018 Aug; 132(7):694-706. PubMed ID: 29907599
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
Verstovsek S; Kantarjian HM; Estrov Z; Cortes JE; Thomas DA; Kadia T; Pierce S; Jabbour E; Borthakur G; Rumi E; Pungolino E; Morra E; Caramazza D; Cazzola M; Passamonti F
Blood; 2012 Aug; 120(6):1202-9. PubMed ID: 22718840
[TBL] [Abstract][Full Text] [Related]
18. Myelofibrosis: an update on drug therapy in 2016.
Bose P; Verstovsek S
Expert Opin Pharmacother; 2016 Dec; 17(18):2375-2389. PubMed ID: 27774820
[TBL] [Abstract][Full Text] [Related]
19. Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.
Ostojic A; Vrhovac R; Verstovsek S
Future Oncol; 2011 Sep; 7(9):1035-43. PubMed ID: 21919691
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A single center experience.
Schmohl JU; Groh C; Faul C; Vogel W; Möhle R; Wirths S; Schneidawind D; Kanz L; Bethge WA
Ann Hematol; 2016 May; 95(6):973-83. PubMed ID: 27021303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
